BYD Launched BAO 5 under Its New Brand FANGCHENGBAO and the DMO Technology
4.9.2023 12:43:00 EEST | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles and power batteries, introduced FANGCHENGBAO, its new professional personalized sub-brand, as well as its sophisticated technology: the Dual Mode Off-road (DMO) Super Hybrid Platform. The first model of the new brand - BAO 5, a super hybrid off-road SUV harnessing the DMO technology was launched during the event as well as a concept car BAO 8 and BAO 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230817807422/en/
Wang Chuanfu, the Chairman and President of BYD (Photo: Business Wire)
Wang Chuanfu, the Chairman and President of BYD, said at the launch event that FANGCHENGBAO aspires to redefine vehicular experience by offering an unparalleled blend of professionalism and personalization to global users, driving a profound "revolution" in the NEV landscape, transforming cars into unique, tailor-made assets for every individual.
The Brand: A great leap in New Energy Vehicle Sector
The brand name FANGCHENGBAO, derived from Chinese phonetics, symbolizes a blend of precision ("FANGCHENG" for "formula") and agility ("BAO" for "leopard"), introducing a series of specialized technologies, including the DMO Super Hybrid Off-Road Platform, which is also inaugurated at the event.
FANGCHENGBAO envisions the confluence of state-of-the-art new energy technologies and diverse users' preferences will unlock unprecedented user experience: whether journeying through the vast wilderness, speeding on a racetrack, navigating through bustling cityscapes, or cruising on highways; whether seeking occasional exhilaration or traversing daily commutes, an exclusive driving experience for every scenario is now within reach.
To meet this end, FANGCHENGBAO will integrate BYD's apex technologies, forward-looking designing ethos, and the vertically integrated supply chain system, in order to enrich every vehicle with distinctive tailor-made possibilities.
FANGCHENGBAO symbolizes the fusion of new energy and boundless possibilities, turning every individual's dreams into tangible reality.
The DMO Technology: Unleashing the Might of Electricity for Individual Empowerment
At the event, BYD unveiled the innovative DMO Super Hybrid Off-Road Platform, signaling a significant pivot from traditional gasoline engines. This platform powers the FANGCHENGBAO vehicles, promising a transformative off-road experience while championing energy efficiency, and empowering every user with pinnacle technology.
The DMO combines BYD's Revolutionary Non-Load-Bearing Frame Designed for Hybrids with a specialized off-road hybrid architecture. This integration taps into BYD's expertise in high-performance chassis, intelligent electric four-wheel drive, and off-road powertrains. As a result, DMO strikes an unparalleled balance between vehicle safety, powerful off-roading, and energy consumption.
Instead of traditional modifications that add weight and increase rollover risks, the DMO innovatively fuses the Blade Battery and high-strength steel frame, evolving to the Cell to Chassis (CTC) technology. This not only ensures battery safety during extreme off-road scenarios but also significantly boosts overall vehicle safety.
The platform also boasts features like the longitudinal EHS electric hybrid system and an industry-first off-road rear-drive powertrain, as well as the Xiaoyun longitudinal high-performance engine, delivering a formidable system power of more than 500kW and an unmatched traction of 32,000N. Moreover, DMO vehicles utilize intelligent torque control technology to minimize the turning radius to just 3.4 meters. Also thanks to its powerful drive and precise electronic control, users can effortlessly navigate through swampy terrains, rugged mountains, gravelly slopes, and many other extreme terrains with the DMO. Equipped with three Differential Locks, drivers can switch to low-speed gear, which is designed for off-road scenario, with a push on the button.
Building on this innovative architecture, DMO incorporates a double-wishbone independent suspension at both ends, which, when paired with DiSus-P Hydraulic Body Control System, assures SUV-like comfort even in challenging terrains. The platform achieves 35% fuel savings compared to gasoline-powered off-road vehicles.
DMO stands out as a predominantly electric-driven, professional-grade off-road platform. It represents the culmination of over twenty years of BYD's cutting-edge technological evolution and insights from the experience gleaned from millions of BYD PHEVs. This platform transcends the conventional and substantially amplifies the capabilities of electric mobility. With its vast technical prowess, the DMO surmounts challenges that new energy vehicles typically encountered across scenarios, recalibrating the paradigm for off-road vehicular design and functionality.
Looking ahead, FANGCHENGBAO is set to venture into domains such as off-road SUVs and sports cars, where traditional gasoline vehicles predominate, starting from models with the DMO platform.
The New Models: Pioneers With Leading Technology and Unique Product Offerings
Three FANGCHENGBAO's models offer a powerful product lineup, catering to a range of individual preferences, demonstrating its robust product matrix and its dedication to professionalism and individuality.
The BAO 5, positioned as a super hybrid off-road SUV, is equipped with key technologies like DMO and DiSus-P Hydraulic body control system. Its design seamlessly combines industrial aesthetics with robust power, delivering unparalleled stability and safety for users.
As a brand emphasizing customization, FANGCHENGBAO offers the BAO 5 a variety of front-face structures that can be seamlessly integrated or adjusted. It provides a flexible foundation tailored to each user's unique modification preferences.
The BAO 8 concept car, named SUPER 8, unveils the brand's futuristic vision for off-road SUVs. Inspired by sci-fi battlefields, this design ensures robust integration and enhanced protection, inspiring driver confidence. Furthermore, preliminary details about the BAO 3 were revealed, hinting at a trendy model geared towards diverse audiences with a playful spirit.
To ensure consistent service and experience quality, FANGCHENGBAO will adopt a Direct-to-Consumer (DTC) model in the initial phase in the Chinese market, planning to reach 60 cities by 2024. It is also announced that the BAO 5 will have its first offline debut at the Chengdu Motor Show, starting August 25th.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817807422/en/
Contact information
Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom